Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $12.7 million.

  • Ovid Therapeutics' Operating Expenses fell 555.27% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year decrease of 3215.49%. This contributed to the annual value of $62.5 million for FY2024, which is 465.54% up from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Operating Expenses is $12.7 million, which was down 555.27% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Operating Expenses ranged from a high of $31.8 million in Q1 2021 and a low of $10.8 million during Q4 2024
  • In the last 5 years, Ovid Therapeutics' Operating Expenses had a median value of $14.2 million in 2023 and averaged $15.8 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 5681.9% in 2021, then plummeted by 5363.38% in 2022.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Operating Expenses stood at $26.4 million in 2021, then crashed by 53.63% to $12.2 million in 2022, then soared by 50.01% to $18.3 million in 2023, then plummeted by 41.09% to $10.8 million in 2024, then increased by 17.2% to $12.7 million in 2025.
  • Its Operating Expenses was $12.7 million in Q3 2025, compared to $11.3 million in Q2 2025 and $12.7 million in Q1 2025.